Holen Sie sich die Stockscreener-App
21.81
0.77%
-0.1906
Schlusskurs vom Vortag:
$22.00
Offen:
$21.78
24-Stunden-Volumen:
747.74K
Relative Volume:
0.27
Marktkapitalisierung:
$2.76B
Einnahmen:
$715.22M
Nettoeinkommen (Verlust:
$-250.10M
KGV:
-10.74
EPS:
-2.03
Netto-Cashflow:
$-205.58M
1W Leistung:
+9.48%
1M Leistung:
-12.05%
6M Leistung:
+9.70%
1J Leistung:
-29.03%
1-Tages-Spanne:
$21.45
$22.14
1-Wochen-Bereich:
$19.26
$22.24
52-Wochen-Spanne:
$16.10
$30.91
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Firmenname
Apellis Pharmaceuticals Inc
Sektor
Branche
Telefon
617-977-5700
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Vergleichen Sie APLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
21.80 | 2.78B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-06 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-09-26 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-16 | Eingeleitet | William Blair | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Neutral |
| 2024-02-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-02 | Eingeleitet | Mizuho | Neutral |
| 2023-10-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Bestätigt | Citigroup | Buy |
| 2023-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-17 | Fortgesetzt | Stifel | Buy |
| 2022-04-14 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-09-10 | Bestätigt | Credit Suisse | Neutral |
| 2021-09-10 | Bestätigt | Needham | Buy |
| 2021-09-10 | Bestätigt | Oppenheimer | Outperform |
| 2021-09-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-08-19 | Eingeleitet | Jefferies | Buy |
| 2021-08-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2020-11-19 | Eingeleitet | Needham | Buy |
| 2020-09-01 | Eingeleitet | Stifel | Buy |
| 2020-07-20 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-04-01 | Eingeleitet | Raymond James | Strong Buy |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-11 | Hochstufung | Wedbush | Underperform → Neutral |
| 2020-01-07 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-12-19 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Underperform |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-08-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Aug Retail: Does Apellis Pharmaceuticals Inc stock have upside surprise potentialSell Signal & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Apellis Pharmaceuticals (NASDAQ:APLS) Fits the 'Affordable Growth' Investment Strategy - Chartmill
Apellis Pharma CEO Francois sells $161,945 in stock By Investing.com - Investing.com Canada
Apellis Pharma VP Chopas sells $14k in shares By Investing.com - Investing.com Canada
Apellis Pharma CMO Baumal sells $37k in shares - Investing.com
Nicholson nur, Apellis Pharmaceuticals CTO, sells $43k in APLS stock - Investing.com
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CEO Sells 8,182 Shares of Stock - MarketBeat
James George Chopas Sells 726 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells 909 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells 1,882 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel Sells 2,475 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CFO Sells 2,892 Shares of Stock - MarketBeat
Bank of America Upgrades Apellis Pharmaceuticals (APLS) Amid Suc - GuruFocus
Why Is Apellis Pharma Stock Gaining Wednesday?Apellis Pharmaceuticals (NASDAQ:APLS) - Benzinga
Bank of America Upgrades Apellis Pharmaceuticals to Buy, Highlights Strong Empaveli Launch - Intellectia AI
Apellis upgraded at BofA on Empaveli launch (APLS:NASDAQ) - Seeking Alpha
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Up After Analyst Upgrade - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Upgraded at Bank of America - MarketBeat
Apellis stock rating upgraded by BofA on Empaveli’s commercial potential - Investing.com Canada
APLS Receives Analyst Upgrade to 'Buy' with Maintained Price Tar - GuruFocus
Liquidity Mapping Around (APLS) Price Events - Stock Traders Daily
Wells Fargo Maintains Overweight Rating for APLS, Lowers Price T - GuruFocus
Wells Fargo & Company Issues Pessimistic Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat
Paroxysmal Nocturnal Hemoglobinuria Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | Alexion Pharma, Apellis Pharma, Hoffmann-La Roche, Novartis - Barchart.com
Campbell & CO Investment Adviser LLC Invests $1.21 Million in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis stock crashes 23% in a week: Here's what you should know - MSN
Sobi, Apellis win EU nod for Aspaveli against rare kidney diseases - MSN
Is Apellis Pharmaceuticals’ FDA Win Just the Beginning? - Yahoo Finance
Market Trends: Does Apellis Pharmaceuticals Inc stock have upside surprise potential2025 Stock Rankings & Capital Efficient Trading Techniques - baoquankhu1.vn
Apellis stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Canada
Apellis Pharma VP Chopas sells $19k in shares By Investing.com - Investing.com Canada
Apellis Pharma chief business officer sells $39k in APLS stock - Investing.com Canada
Mark Jeffrey Delong Sells 1,780 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CAO Sells $19,371.87 in Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CFO Sells 3,856 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells 2,618 Shares of Stock - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) CEO Sells $226,027.34 in Stock - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Insider Pascal Deschatelets Sells 2,277 Shares - MarketBeat
David Watson Sells 5,780 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock - MarketBeat
Apellis Pharma CFO Sullivan sells $85,553 in shares By Investing.com - Investing.com Canada
Apellis Pharma general counsel Watson sells $128k in shares By Investing.com - Investing.com Canada
Apellis Stock Crashes 23% in a Week: Here's What You Should Know - Finviz
Press Telegram - FinancialContent
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Down 5.8% on Analyst Downgrade - MarketBeat
Apellis Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say - sharewise.com
Assessing Apellis Pharmaceuticals (APLS) Valuation After 2025 Revenue Update And Pipeline Progress - Sahm
Rising SYFOVRE Demand and Prefilled Syringe Plan Could Be A Game Changer For Apellis Pharmaceuticals (APLS) - Yahoo Finance
Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday? - Benzinga
APLS: Cantor Fitzgerald Lowers Price Target, Maintains Overweigh - GuruFocus
Cantor Fitzgerald Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $35.00 - MarketBeat
Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):